INTRODUCTION
Menière's disease was first described by Prosper Menière in 1861. Although involvement of the inner ear is generally agreed upon, there is no accepted theory regarding the pathophysiology. Hypothesized mechanisms based on laboratory and histological evidence include the disruption of longitudinal flow or malabsorption within the endolymphatic duct leading to endolymphatic hydrops [1] . Menière's disease is generally characterized as idiopathic, although speculation for the cause of this disease has included infection, inflammation, autoimmune disorders as well as allergy [1] . This review will focus on the most recent literature discussing the contribution of allergy to the development of Menière's disease.
MENIÈ RE'S DISEASE
Menière's disease is characterized by a constellation of symptoms including fluctuating sensorineural hearing loss, episodic vertigo, tinnitus and aural pressure. The American Academy of Otolaryngology's (AAO) Committee on Hearing and Equilibrium published diagnostic guidelines for Menière's disease in 1995 as follows: previously published in [2] . In addition to history and symptoms suggestive of Menière's disease, objective testing utilizing electrocochleography (ECochG) can be performed. ECochG examines the ratio of the summation potential of the hair cells to the action potential of the synchronized firing of the cochlear nerve. A summation potential/action potential ratio of 0.5 or greater has been correlated with Menière's disease symptoms [3] .
Pathogenesis of Menière's disease is unknown; however a theory of fluid disruption leading to hydropic distention of the endolymphatic sac has been postulated [1] . Initial treatment includes diuretics and low sodium diet. Progressively more invasive treatments to prevent hearing loss and ultimately control vestibular symptoms with sacrifice of hearing include intratympanic injection of steroids, intratympanic gentamicin injections, endolymphatic sac surgery, vestibular nerve section and labyrinthectomy [4] .
ALLERGY
The association of allergy and Menière's disease first appeared in the literature in 1923 [5] . Two cases were described of patients with symptoms consistent with Menière's disease. Each was treated with epinephrine and symptoms resolved. Much of the current literature supporting this association has come from the work of Derebery. Among crosssectional surveys, the prevalence of diagnosed allergy was three times higher in those with a history of Menière's disease compared with the general population [6] . More specifically, of those with Menière's disease, 58% had a history of allergy and 41% had a positive skin test [6] . Patients with the disease have been shown to have a 'heightened immune' reaction. Subjects with a history of Menière's disease had elevated IgE levels compared with control groups (43.3% of subjects vs. 19.5%) [7] . Savastano et al. [8] found elevated immune complexes, interleukins, and autoantibodies in patients diagnosed with Menière's disease. Additionally, disease severity was associated with elevated immune complexes as well as an elevated CD4:CD8 ratio [8] .
Derebery and Berliner [9] describe three theories relating allergy to Menière's disease that center on inflammation within the endolymphatic sac. First, the endolymphatic sac contains a fenestrated blood supply that may allow antigen entry leading to mast cell degranulation and inflammation. A second proposed mechanism involves circulating immune complexes that enter endolymphatic sac circulation and the stria vascularis leading to inflammation and increased permeability as well as fluid balance disruption. A final theory pertains to a viral antigenallergic interaction. Viruses have been shown to exacerbate allergic symptoms by enhancing histamine release and can damage epithelial surfaces as well as trigger T-cell migration to the endolymphatic sac [8] .
Both inhalant and food allergies have been associated with Menière's disease. In Derebery's [6] work, wheat (gliadin) was the most common food allergen in Menière's disease patients. More recently, Di Beradino and Cesarani [10 & ] performed a study to verify the incidence of gliadin IgE hypersensitivity in Menière's disease patients. Patients with Menière's disease not currently being pharmacologically treated were recruited and compared with two control groups. One group consisted of healthy volunteers, whereas a second control group consisted of patients with grass pollen rhinoconjunctivitis. Prick testing to common inhalant and food allergens including gliadin was performed. Mean wheal diameter was measured and compared against a histamine control. Of subjects with Menière's disease, eight out of 33 were positive to gliadin at 20 min (early phase response) with the remaining 25 subjects showing a late-phase positive response. Gliadin prick test was negative for both control groups.
With data to show that patients with Menière's disease develop a robust allergic response, Topuz et al.'s [11] study illustrates an association with allergy exposure, subsequent allergic response, and the development of endolymphatic hydrops. Patients, recruited by phone, were classified as
KEY POINTS
Animal studies have shown evidence that antigen exposure leads to an increase in allergic markers that can trigger development of endolymphatic hydrops.
Premedication with leukotriene antagonists in animals can limit the development of an immune response within the inner ear.
Supporting prior research, incidence of gliadin IgE hypersensitivity is greater in patients with Menière's disease.
The association of migraine with allergy co-morbidities and Menière's disease needs to be explored as a potential confounder.
Menière's disease based upon audiogram and ECochG. Prick test for dietary and inhalant allergens was performed and ECochG was obtained 30-45 min after exposure. A second provocation phase was performed wherein patients were given a second exposure to the antigen with the greatest induration. After provocation, 62.5% of patients subjectively reported tinnitus and aural fullness, whereas 12.5% experienced vertigo. Before prick test, 28.7% of ears had a summation potential/action potential of 0.5 or greater. Postprick test and provocation, the number increased to 77.5 and 72.5%, respectively. Interestingly, in normal ears, a similar finding was noted. These data provided evidence that with allergic exposure, there appears to be a temporal sequence leading to the development of the disease. The authors also concluded that antigen exposure triggered a histaminergic reaction, leading to inflammation in the endolymphatic sac and potentially manifesting as symptoms of Menière's disease.
To support the theory that the endolymphatic sac appears to be a target for allergic activity, histamine receptors have been found within the sac. In animal studies, Dagli et al. [12] showed immunohistochemical evidence of H 1 and H 2 receptors and weakly immunoreactive H 3 receptors. Although not approved for use in the United States, betahistine has been used extensively in Europe as a treatment for Menière's disease. Betahistine is a structural analog of histamine and acts as a weak H 1 receptor agonist and strong antagonist on H 3 receptors. Its mechanism is thought to decrease the release of histamine, dopamine, gamma aminobutyric acid, acetylcholine, norepinephrine, and serotonin and improve microcirculation in the inner ear. In a retrospective analysis, Lezius et al. [13] examined patients with Menière's disease who received high doses (288-480 mg/day) of betahistine and found that with increasing dosage of the medication, the number of patients reporting vertiginous attacks was lower. Most common side-effects were gastrointestinal complaints, fatigue, and altered taste. The authors concluded betahistine is a potent, well tolerated, and effective treatment for Menière's disease.
As another marker of allergy, Takeda et al. [14 && ] performed a study examining plasma arginine vasopressin (p-AVP) and endolymphatic volume. P-AVP has been known to be elevated during allergic insults, whereas endolymphatic volume has been shown to increase with rising p-AVP. In this study, guinea pigs were sensitized with an allergic antigen. Histological examinations were performed at various time points postprovocation. Cross-sectional area of the scala media was used to assess changes in endolymphatic volume and compared with control animals injected with saline. In a second experiment, animal subjects received oral administration of pranlukast hydrate, a leukotriene antagonist. Histological exam included toluidine blue stain to assess for mast cells. In a third experiment, prior to antigen exposure, animal subjects were given pranlukast and compared with subjects given saline. P-AVP was then measured in both groups.
In animal subjects exposed to antigen without pranlukast premedication, results showed evidence of endolymphatic hydrops in all turns of the cochlea. However, animals premedicated with pranlukast did not develop endolymphatic hydrops. Staining in the experimental group showed large cells stained with toluidine blue consistent with mast cells. P-AVP levels were elevated in the sensitized group; however, among those premedicated with pranlukast, levels were statistically lower. Not only did this provide evidence that a systemic immune challenge could provoke an allergic reaction in the inner ears, the authors showed evidence of a decreased immune response when premedicated with a leukotriene antagonist.
Research regarding treatment of allergy as it relates to Menière's disease in humans has been limited. Patients using allergy immunotherapy and food elimination treatments have reported improved symptoms including decreased severity and frequency of episodes and decreased tinnitus and vertigo as compared with controls [6] . In a prospective study, patients rated symptoms before and after treatment and noted decreased severity of symptoms [9] . Derebery and Berliner [9] concluded by recommending allergy testing for patients with Menière's disease if indicated. Such indications include history of seasonal or food allergy, childhood or family history of allergy, bilateral Menière's symptoms, or a development of symptoms within a short time after exposure of food or inhaled allergen. No recent studies including randomized controlled studies have been performed.
CONFOUNDERS
Banks et al. [15 & ] provide the most recent literature review summarizing the association of allergy and Menière's disease. Much of the literature is based on cross-sectional or observational data without analysis for potential confounders. One area that has been highlighted is the association of allergy with migraine and Menière's disease. Through survey data collection, Sen et al. [16] found a significantly higher incidence of allergy and migraine in patients diagnosed with Menière's disease. Moreover, the incidence of allergy in the Menière's disease-migraine group was significantly higher than in the group with Menière's disease alone.
In a more rigorous study, Radtke et al. [17] recruited patients with Menière's disease as diagnosed by AAO criteria. Individuals were age and sex matched to control subjects. All subjects then underwent a semi-structured interview exploring lifetime prevalence of migraine. Results showed a higher lifetime prevalence of migraine among those with Menière's disease as compared with controls (56 vs. 25%) [17] . Authors speculated the high prevalence may be secondary to patients having migrainous vertigo or potentially a true physiological link between Menière's disease and migraine.
These studies bring to light the possibility of migraine as a confounder in the association of allergy and Menière's disease. Mehle contributor. An association may be plausible given the scientific evidence and reported control of symptoms with treatment of allergies. Prescribing allergy control as part of a Menière's disease treatment plan may not be unreasonable, given that allergy avoidance is low risk to the patient, particularly those with a history of inhalant or food allergies. If a significant allergy is identified, the use of immunotherapy may be weighed against potential side-effects. Clearly, more rigorously designed studies should be performed to fully examine this relationship.
CONCLUSION
Menière's disease, although described more than 150 years ago, is still considered an idiopathic disease. Continued research is needed to further understand the cause to assist in treatment. An association between allergy and Menière's disease has been shown in cross-sectional and observational studies while animal studies have shown evidence of allergic activity within the inner ear. Further studies are needed to demonstrate this association via well designed randomized trials with inclusion of potential confounders. However, given the low risk to patients, inclusion of allergy avoidance and immunotherapy should be considered as part of the treatment plan to help patients control Menière's disease symptoms.
